<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01699217</url>
  </required_header>
  <id_info>
    <org_study_id>CML0912</org_study_id>
    <nct_id>NCT01699217</nct_id>
  </id_info>
  <brief_title>Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase</brief_title>
  <acronym>CML0912</acronym>
  <official_title>Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GIMEMA CML Working Party promotes a multicentre, observational, prospective study of CML&#xD;
      patients treated frontline with NIL. Patients will be followed for 5 years. This study will&#xD;
      help the definition of guidelines for the treatment of CML patients in early CP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to describe the stability of molecular response with&#xD;
      NIL as frontline therapy in newly diagnosed, unselected, CP CML patients, in an independent,&#xD;
      investigator-initiated observational study. Imatinib mesylate (IM), a protein tyrosine kinase&#xD;
      inhibitor (TKI) targeting BCR-ABL, has become in the last decade the standard of care for&#xD;
      Chronic Myeloid Leukaemia (CML) in chronic phase (CP)1,2. Nilotinib (NIL) is a second&#xD;
      generation TKI, effective in IM-resistant and IM-intolerant patients, which demonstrated&#xD;
      superior efficacy to IM in early CP BCR-ABL+ CML patients3. Currently, the most important&#xD;
      target of the treatment of CML with TKIs is the major molecular response (MMR), defined as a&#xD;
      ≥ 3 log reduction in BCR-ABL/ABL transcript level, marker of better long-term outcome. With&#xD;
      imatinib therapy, achieving a MMR correlates with an improved probability of a durable&#xD;
      cytogenetic remission30. Results from IRIS suggest that a MMR after 12 months of imatinib&#xD;
      therapy may be a marker of stable response. Further on, the IRIS study showed that patients&#xD;
      with a MMR after 12 months of therapy had a significantly better probability of disease-free&#xD;
      survival compared with those in complete cytogenetic remission, but not in MMR31. Moreover,&#xD;
      obtaining an undetectable BCR-ABL transcript level is extremely relevant in order to consider&#xD;
      TKIs discontinuation. This condition is known as &quot;Complete Molecular Response&quot; (CMR) and is&#xD;
      further defined according to the sensitivity achieved (for the definition see the &quot;Criteria&#xD;
      of evaluation&quot; section). As far as treatment discontinuation, two experiences have been&#xD;
      published so far, aimed at evaluating the persistence of the CMR after imatinib&#xD;
      discontinuation. The first was a pilot study32 where 12 patients were included. These 12&#xD;
      patients discontinued imatinib after at least 2 years of CMR (median duration of negativity,&#xD;
      32 months). Six patients displayed a molecular relapse with a detectable BCR-ABL transcript&#xD;
      at 1, 1, 2, 3, 4, and 5 months. Imatinib was then reintroduced and led to a novel molecular&#xD;
      response. Six other patients (50%) still have an undetectable level of BCR-ABL transcript&#xD;
      after a median follow-up of 18 months (range, 9-24 months). The results of this pilot trial&#xD;
      have been confirmed and extended in a second trial, the STIM trial33: 100 patients were&#xD;
      enrolled, median follow-up 17 months, 69 patients with at least 12 months follow-up: 42 (61%)&#xD;
      of these 69 patients relapsed (40 before 6 months, one patient at month 7, and one at month&#xD;
      19). At 12 months, the probability of persistent CMR for these 69 patients was 41% (95% CI&#xD;
      29-52). All patients who relapsed responded to reintroduction of imatinib. An increase of the&#xD;
      CMR rate could possibly translate in a higher proportion of patients candidate to stopping&#xD;
      anti-CML treatment, with higher probability of remaining disease-free in the long term. The&#xD;
      advantages of this possible future scenario could be: first, the possibility of treatment&#xD;
      discontinuation at least in patients with chronic clinical adverse events; second, a&#xD;
      potential reduction of the costs of TKI treatment (after the introduction of TKI, the costs&#xD;
      of CML treatment is increasing year by year, with the increasing prevalence of CML patients).&#xD;
      Standardized molecular monitoring has become widely available in Europe through the efforts&#xD;
      of EUTOS cooperation19 and now allows for the generation of comparable data on the residual&#xD;
      disease using recalculation on the international scale despite these data being analyzed in&#xD;
      many different laboratories. These advances in the standardization of molecular responses and&#xD;
      the improvement of targeted therapy have allowed for comparable response assessment across&#xD;
      Italian Centres and early treatment optimization of patients.&#xD;
&#xD;
      In summary, 1) monitoring of molecular response and of deep and sustained molecular response,&#xD;
      provides a straightforward opportunity to assess patients' response and possible prognosis in&#xD;
      the use of targeted therapy. 2) Most data on second generation TKIs are from&#xD;
      company-sponsored studies generally implemented in selected referral centres. 3) The detailed&#xD;
      description of the kinetic of the molecular response and, particularly, the rate of stable&#xD;
      MR4, potentially related in turn with a subsequent treatment discontinuation, within the&#xD;
      frame of a long-term post-marketing surveillance observational trial offered to all eligible&#xD;
      patients followed at a nation-wide, independent multicentre group is the core distinctive&#xD;
      feature of this observational trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of confirmed MR4</measure>
    <time_frame>At 24 months from study entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of MMR</measure>
    <time_frame>At 24, 36, 48, and 60 months from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of MR4</measure>
    <time_frame>At 24, 36, 48, and 60 months from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of MR4.5</measure>
    <time_frame>At 24, 36, 48, and 60 months from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of confirmed MR4</measure>
    <time_frame>At 36, 48, and 60 months from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of stable MR4</measure>
    <time_frame>At 24, 36, 48, and 60 months from study entry</time_frame>
    <description>(at least three PCR results with MR4 within the last year [± 2 months] and no results &gt; 0.01% during the same period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of stable MR4.5</measure>
    <time_frame>At 24, 36, 48, and 60 months from study entry</time_frame>
    <description>(at least three PCR results with MR4.5 within the last year [± 2 months] and no results &gt; 0.0032% during the same period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of confirmed loss of MMR (MR3)</measure>
    <time_frame>At 60 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of confirmed loss of MMR</measure>
    <time_frame>At one year from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Complete Cytogenetic Response</measure>
    <time_frame>At one year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of permanent NIL discontinuation</measure>
    <time_frame>At 5 years from study entry</time_frame>
    <description>(for failure [defined according to ELN recommendations 2009], intolerance, and death for any reason; not for patients in ≥ MR4 entering clinical trials exploring nilotinib discontinuation)</description>
  </secondary_outcome>
  <enrollment type="Actual">127</enrollment>
  <condition>Chronic Phase Philadelphia Positive</condition>
  <condition>BCR-ABL Positive</condition>
  <condition>Chronic Myeloid Leukaemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment decision is at the discretion of the investigator and must not be made on the&#xD;
        basis of this observational study. Patients should have their treatment initiated in&#xD;
        accordance with the summary of product characteristics.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: &gt;=18 years;&#xD;
&#xD;
          -  Patients with chronic phase Ph+ and/or BCR-ABL+ CML, newly diagnosed (less than 6&#xD;
             months);&#xD;
&#xD;
          -  Prior treatment with Hydroxyurea or Anagrelide is allowed;&#xD;
&#xD;
          -  Prior treatment with IM for less than 30 days is allowed;&#xD;
&#xD;
          -  Signed written informed const according to ICH/EU/GCP and national local laws.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are pregnant (negative pregnancy test is requested within 2 days before&#xD;
             nilotinib start) or breast feeding, or adults of reproductive potential not employing&#xD;
             an effective method of birth control.&#xD;
&#xD;
          -  Newly diagnosed Ph+ and/or BCR-ABL+ CML patients in advanced phases (accelerated or&#xD;
             blastic phase).&#xD;
&#xD;
          -  Prior treatment with nilotinib, dasatinib, or other tyrosine-kinase inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianantonio Rosti, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology and Oncological Sciences, S.Orsola-Malpighi Hospital, University of Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Nuovo Ospedale &quot;Torrette&quot;</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Area Medica - Presidio Ospedaliero &quot;C. e G.Mazzoni&quot;</name>
      <address>
        <city>Ascoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia con trapianto-Università degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USD Trapianti di midollo per adulti - Cattedra di Ematologia - Università degli Studi di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale A. Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Onco-Ematologia - Centro di Ricerca e Formazione ad Alta tecnologia nelle Scienze Biomediche</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Dipartimentale - Centro per le malattie del sangue - Ospedale Civile - S.Giacomo</name>
      <address>
        <city>Castelfranco Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ezione di Ematologia C.T.M.O. Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce Divisione di Ematologia Cuneo</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Careggi, Università delgi studi di Firenze</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Ematologia Ospedali Riuniti Foggia - Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - DiMI - Università degli Studi di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11°piano- lato ponente</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOC Ematologia e Centro Trasfusionale Ospedale di Ivrea - ASL TO4</name>
      <address>
        <city>Ivrea</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale &quot;Santa Maria Goretti&quot;</name>
      <address>
        <city>Latina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot;</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Centro Trapianti di Midollo - IRCCS Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Università degli Studi di Napoli &quot;Federico II&quot; - Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gennaro - ASL Napoli 1</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sez. di Ematologia Clinica Ospedale San Francesco</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2 Prof. Giuseppe Saglio</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Padova - Ematologia ed Immunologia Clinica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia con trapianto di midollo - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Maddalena Casa di Cura di Alta Specialità Dipartimento Oncologico di III Livello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia CTMO Università degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. di Ematologia di Muraglia - CTMO Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Pisa - Azienda Ospedaliera Pisana - Dipartimento di Oncologia, dei Trapianti e delle nuove Tecnologie in Medicina - Divisione di Ematologia</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico - Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia - Centro Oncologico Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera &quot;Sant' Andrea&quot;-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complesso Ospedaliero S. Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pronto Soccorso e Accettazione Ematologica - Dipartimento Biotecnologie Cellulari ed Ematologia - Università degli Studi di Roma &quot;Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segreteria di Ematologia - S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale Viterbo - Polo Ospedaliero Centrale - Ospedale Di Ronciglione - U.O. di Ematologia</name>
      <address>
        <city>Ronciglione</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>S. G. Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico &quot; Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SS.C. di Oncoematologia - Dipartimento di Medicina Clinica e Sperimentale - Azienda Ospedaliera - S. Maria Di Terni</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia - Med.II Div. Presidio Ospedaliero S. Chiara di Trento</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda U.L.S.S.9 - U.O. di Ematologia</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 1, 2012</study_first_submitted>
  <study_first_submitted_qc>October 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2012</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myeloid Leukaemia</keyword>
  <keyword>Philadelphia positive</keyword>
  <keyword>BCR-ABL positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

